Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash & Equivalents: 2021-2025

Historic Cash & Equivalents for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $392.6 million.

  • Krystal Biotech's Cash & Equivalents rose 4.98% to $392.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.6 million, marking a year-over-year increase of 4.98%. This contributed to the annual value of $344.9 million for FY2024, which is 3.76% down from last year.
  • Per Krystal Biotech's latest filing, its Cash & Equivalents stood at $392.6 million for Q3 2025, which was up 10.96% from $353.8 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Cash & Equivalents registered a high of $402.2 million during Q1 2021, and its lowest value of $140.7 million during Q1 2023.
  • Over the past 3 years, Krystal Biotech's median Cash & Equivalents value was $353.8 million (recorded in 2025), while the average stood at $329.7 million.
  • In the last 5 years, Krystal Biotech's Cash & Equivalents plummeted by 52.56% in 2022 and then skyrocketed by 155.08% in 2024.
  • Krystal Biotech's Cash & Equivalents (Quarterly) stood at $341.2 million in 2021, then slumped by 52.56% to $161.9 million in 2022, then soared by 121.33% to $358.3 million in 2023, then decreased by 3.76% to $344.9 million in 2024, then climbed by 4.98% to $392.6 million in 2025.
  • Its Cash & Equivalents was $392.6 million in Q3 2025, compared to $353.8 million in Q2 2025 and $308.8 million in Q1 2025.